To Determine the Seroprevalance of Hepatitis B Surface Antigen (HBsAg) and ANTI-HCV Antibodies in Patients Undergoing Haemodialysis
Abstract: Hepatitis B and C is globally one of the most common and severe infectious diseases that leads to significant morbidity and mortality. As such chronic kidney disease is an immune-deficient state, hence blood-borne viral infection particularly HBV and HCV are an important cause of morbidity and mortality of patients treated by haemodialysis. Patients who have undergone haemodialysis for end-stage renal failure are at a higher risk for infections. Aim of the study was to determine the seroprevalence of hepatitis B surface antigen (HBsAg) and Anti-HCV antibodies in patients undergoing Haemodialysis. Serological test for Hepatitis B & Anti-HCV was done by immuno-chromatographic HBsAg and Anti-HCV kit or by CLIA. Immunodiagnostic System. Prevalence of HCV (50.7 %) was slightly higher than that of HBsAg (49.23 %) out the positive cases (65/695) in the Hemodialysis patient. Among the 65 patients, majority i. e.75 % HBsAg and 69 % Anti-HCV reactive were those who underwent dialysis
Keywords: HBsAg, Anti-HCV, Haemodialysis
How to Cite?: Krishna Kant Sharma, Rahul Soni, Dr. Sweta Gupta, "To Determine the Seroprevalance of Hepatitis B Surface Antigen (HBsAg) and ANTI-HCV Antibodies in Patients Undergoing Haemodialysis", Volume 9 Issue 11, November 2020, International Journal of Science and Research (IJSR), Pages: 674-676, https://www.ijsr.net/getabstract.php?paperid=SR201111143914, DOI: https://dx.doi.org/10.21275/SR201111143914